Even as many things change in the drug industry, at least one fact should
stay the same in the coming years, according to analysts
at EvaluatePharma. AbbVie's megablockbuster Humira will lead the world's
drug sales charts in 2024, according to a new report, representing a
record-breaking run that has lifted the company's fortunes along the way. After generating sales of $18.9 billion last year, Humira will turn in
$15.23 billion in 2024 sales, according to the analysts' new World Preview
2018, representing a 3% annual slip during the period. Jefferies
analysts have predicted sales for the drug will peak at $20.9 billion next
year.